文献速递胸部肿瘤放疗放疗物理与技术

非小细胞肺癌治疗中期FDG-PET体积下降更大可能与更差生存相关

Greater reduction in mid-treatment FDG-PET volume may be associated with worse survival in non-small cell lung cancer.
PubMed 文献 · Radiother Oncol · 2018-10-30

本研究纳入102例I-III期非小细胞肺癌患者,放疗40-50 Gy时复查FDG-PET-CT,检验治疗中期FDG-PET参数变化能否预测总生存,以及PET引导的自适应治疗能否改善生存。结果显示治疗中期MTV与TLG变化与总生存相关,MTV下降更大在常规放疗组与更差生存相关、在PET引导自适应治疗组与更好生存相关。

要点

  • 治疗中期MTV变化(P=0.021)与总生存相关,NSUVmax、NSUVmean和CT-GTV变化与总生存无关(均P>0.1)。
  • 常规放疗(60-70 Gy)中MTV下降大于均值者中位生存14个月,小于均值者22个月。
  • PET引导自适应放疗中MTV下降大于均值者中位生存33个月,小于均值者19个月。

核心结论

  • 治疗中期PET体积参数变化与NSCLC生存显著相关;MTV下降更大在标准放疗患者中与更差生存相关,而在治疗中期PET引导自适应治疗患者中与更好生存相关。

研究设计与样本

  • 研究纳入需要每日分次放疗的I-III期NSCLC患者,共102例接受三维适形放疗,其中30例接受治疗中期PET引导的剂量递增放疗。
  • 患者在放疗前及放疗40-50 Gy时行FDG-PET-CT扫描,统一测量NSUVmax、NSUVmean、MTV、TLG和CT-GTV,主要终点为总生存。

主要发现

  • 所有PET-CT参数在治疗中期均显著下降(P<0.001),FDG体积参数下降幅度大于FDG活性参数。
  • 治疗中期MTV变化(P=0.053)和TLG变化(P=0.021)与总生存相关,NSUVmax、NSUVmean和CT-GTV变化与总生存无关(均P>0.1)。
  • 常规放疗(60-70 Gy)患者中,MTV下降大于均值者中位生存14个月,小于均值者中位生存22个月。
  • 治疗中期PET引导放疗患者中,MTV下降大于均值者中位生存33个月,小于均值者中位生存19个月。
  • 总体而言,PET引导治疗较常规放疗的5年生存率提高19%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: This study tested the hypotheses that 1) changes in mid-treatment fluorodeoxyglucose (FDG)-positron emission tomography (PET) parameters are predictive of overall survival (OS) and 2) mid-treatment FDG-PET-adapted treatment has the potential to improve survival in patients with non-small cell lung cancer (NSCLC). MATERIAL AND METHODS: Patients with stage I-III NSCLC requiring daily fractionated radiation were eligible. FDG-PET-CT scans were obtained prior to and mid-treatment with radiotherapy at 40-50 Gy. The normalized maximum standardized uptake value (NSUVmax), normalized mean SUV (NSUVmean), PET-metabolic tumor volume (MTV), total lesion glycolysis (TLG), and computed tomography-based gross tumor volume (CT-GTV) were consistently measured for all patients. The primary study endpoint was OS. RESULTS: The study is comprised of 102 patients who received 3-dimensional conformal radiotherapy, among whom 30 patients who received mid-treatment PET-adapted dose escalation radiotherapy. All PET-CT parameters decreased significantly (P < 0.001) mid-treatment, with greater reductions in FDG-volumetric parameters compared to FDG-activity factors. Mid-treatment changes in MTV (P = 0.053) and TLG (P = 0.021) were associated with OS, while changes in NSUVmax, NSUVmean, and CT-GTV were not (all Ps>0.1). Patients receiving conventional radiation (60-70 Gy) with MTV reductions greater than the mean had a median survival of 14 months, compared to those with MTV reductions less than the mean who had a median survival of 22 months. By contrast, patients receiving mid-treatment PET-adapted radiation with MTV reductions greater than the mean had a median survival of 33 months, compared to those with MTV reductions less than the mean who had a median survival of 19 months. Overall, PET-adapted treatment resulted in a 19% better 5-year survival than conventional radiation. CONCLUSION: Changes in mid-treatment PET-volumetric parameters were significantly associated with survival in NSCLC. A greater reduction in the mid-treatment MTV was associated with worse survival in patients treated with standard radiation, but with better survival in patients who received mid-treatment PET-adapted treatment.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Kong FS, Li L, Wang W, et al. Greater reduction in mid-treatment FDG-PET volume may be associated with worse survival in non-small cell lung cancer. Radiother Oncol. 2018. PMID: 30389239. doi:10.1016/j.radonc.2018.10.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。